Revance Therapeutics, Inc.

Revance Therapeutics, Inc. (United States) is linked to 1 FDA-registered manufacturing site. 1 FDA enforcement record is linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Revance Therapeutics, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/revance-therapeutics-inc

Overview

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product known as DaxibotulinumtoxinA. The company aims to redefine patient and physician competencies in the field of neuromodulation.

Therapeutic areas

AestheticsNeurology

Registered manufacturing sites (1)

Physical sites registered with the US FDA and resolved to Revance Therapeutics, Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

1 FDA enforcement record linked to this company.

  • 4832025-02-27

    Scientifically sound laboratory controls

For suppliers

Is this Revance Therapeutics, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.